Preferences help
enabled [disable] Abstract
Number of results
2013 | 8 | 3 | 317-321
Article title

HLA antibody screening strategy in patients awaiting kidney transplantation

Title variants
Languages of publication
Physical description
1 - 6 - 2013
17 - 4 - 2013
  • Tissue Typing Compartment, Department for laboratory testing, Institute for Blood Transfusion of Vojvodina, Hajduk Veljkova 9a, 21000, Novi Sad, Serbia
  • Tissue Typing Compartment, Department for laboratory testing, Institute for Blood Transfusion of Vojvodina, Hajduk Veljkova 9a, 21000, Novi Sad, Serbia
  • [1] Slavcev A. Donor-specific antibodies and kidney transplant rejection. Annals of Transplantation 2003; 8(3):12–15
  • [2] Muro M, Ljorenze S, Marin L, Moya-Quiles MR, et al. Acute vascular rejection mediated by HLA antibodies in a cadaveric kidney recipient: discrepancies between FlowPRATM, ELISA and CDC vs luminex screening. Nephrology Dialysis Transplantation 2005;20:223–226[Crossref]
  • [3] Amico P, Honger G, Mayr M, Schaub S. Detection of HLA antibodies prior renal transplantation: prospects and limitations of new assays. Swiss Medical Weekly 2008; 138(33–34):472–476
  • [4] Pelletier RP, Adams PW, Hennessy PK, Orosz CG. Comparison of crossmatch results obtained by ELISA, flow cytometry, and conventional methodologies. Humman Immunology 1999; 60(9):855–861[Crossref]
  • [5] Goggins R, Geiselhart L. Antibody screening beyond tears. ASHI Qarterly. Second Quarter 2003:70–72
  • [6] Moise A, Nedelcu D, Toader A, Sora M, Tica A, Ferastraoaru DE, Constantinescu I. Cytotoxic antibodies - valuable prognostic factor for long term kidney allograft survival. Journal of Medicine and Life 2010; 3(4):390–395
  • [7] Lucas DP, Paparounis ML, Myers L, Hart JM, et al. Detection of HLA class I-specific antibodies by the QuickScreen Enzyme-Linked Immunosorbent Assay. Clinical and Diagnostic Laboratory Immunology 1997; 4(3):252–257
  • [8] Tait BD, Hudson F, Cantwell L, Brewin G, et al. Luminex technology for HLA antibody detection in organ transplantation. Nephrology 2009; 14:247–254[Crossref][WoS]
  • [9] Minucci PB, Grimaldi V, Casamassimi A, Cacciatore F, et al. Methodologies for Anti-HLA Antibody Screening in Patients Awaiting Kidney Transplant: A Comparative Study. Experimental and Clinical Transplantation 2011; 9(6):381–386
  • [10] Lefaucheur C, Loupy A, Hill GS, Andrade J, et al. Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation. Journal of the American Society of Nephrology 2010;21:1398–1406[Crossref]
  • [11] Altermann WW, Seliger B, Sel S, Wendt D, et al. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. Histology and Histopathology. 2006; 21:1115–1124
  • [12] Schlaf G, Pollok-Kopp B, Manzke T, Schurat O et al. Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and posttransplant crossmatching. Nephrology Dialysis Transplantation. 2010; 3:527–538
  • [13] Puttarajappa C, Shapiro R, Tan HP. Antibody-Mediated Rejection in Kidney Transplantation: A Review. Journal of Transplantation. 2012:193724
  • [14] Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2(7465):662–665.[Crossref]
  • [15] Kao KJ, Scornik JC, Small SJ. Enzyme-linked immunoassay for anti-HLA antobodies - an alternative to panel studies by lymphocytotoxicity. Transplantation 1993; 55(1):192–196[Crossref]
  • [16] Moore BA, Ploeger NA, DeGoey SR. HLA antibody screening: Comparison of a solid phase Enzyme-Linked Immunoassay with antiglobulin-augmented lymphocytotoxicity. Transplantation 1997; 64(11):1617–1620[Crossref]
  • [17] Braun WE. Laboratory and clinical management of the highly sensitized organ transplant recipient. Humman Immunology 1989; 26(4):245–260[Crossref]
  • [18] Kang E-S, Kim S-J, Choi KB, Chung KY. Continuous monitoring of donor specific anti-HLA antibody in kidney transplantation patients. The Journal of the Korean Society for Transplantation 2009; 23:227–232[Crossref]
  • [19] Slavcev A, Lacha J, Sajdlova H, Vitko Š, et al. Characterisation of patient antibodies after kidney transplantation. Annals of Transplantation 2001; 6(2):12–15
  • [20] Tiercy JM, Cattin S, Pongratz G, Goumaz C, et al. A complementary strategy for pretransplant HLA antibody screening. Transplant Proceedings 2002; 34:850–851[Crossref]
  • [21] Worthington JE, Langton A, Liggett H, Robson AJ, et al. A novel strategy for the detection and definition of HLA-specific antibodies in patients awaiting renal transplantation. Transplant International 1998; Suppl 1:S372–S376
  • [22] Fernandez-Fresnedo G, Pastor JM, Lopez-Hoyos M, Ruiz JC, et al. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival. Nephrology Dialysis Transplantation 2003; 18:990–995[Crossref]
  • [23] Arnold ML, Zacher T, Dechant M, Kalden JR, et al. Detection and specification of noncomplement binding anti-HLA alloantibodies. Humman Immunology 2004; 65(11):1288–1296[Crossref]
  • [24] Flesch B. Laboratory diagnostics of HLA antibodies. Laboratoriums Medizin 2003; 27(9–10):351–458[Crossref]
  • [25] Jaramillo A, Smith MA, Phelan D, Sundaresan S, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progresive decline in pulmonary function after lung transplantation. Transplantation 1999; 67(8):1155–1161[Crossref]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.